Regulatory and Legislative Crackdown on PBMs and Vertical Integration

The highly integrated business model of modern managed care—which combines health insurance, Pharmacy Benefit Managers (PBMs), and retail/specialty pharmacies—is facing an escalating, multi-front regulatory, legislative, and legal assault. In Q2 2026, federal and state lawmakers intensified their efforts to force structural divestitures of pharmacies from PBMs and insurers, while PBMs launched aggressive legal defenses using federal preemption doctrines.

Bipartisan PBM Act Reintroduced with Accelerated Divestment Timelines

On May 13, 2026, bipartisan sponsors in both chambers of Congress reintroduced the Patients Before Monopolies Act (PBM Act) (H.R. 8779 / S. 5503). This legislation targets the core economic engine of vertically integrated managed care by making it unlawful to directly or indirectly own or control both a pharmacy and any insurance company or PBM.

The 2026 version of the bill includes dramatically strengthened enforcement mechanisms compared to the initial 2024 draft:

Accelerated Timeline: The divestment window has been slashed from three years to one year, with the FTC and DOJ Antitrust Division required to issue clear milestones within 30 days of enactment.
Severe Financial Penalties: Violators who fail to meet divestment milestones must transfer 10% of their monthly profits into an escrow account. If they miss the final deadline, a court-appointed trustee will step in to sell the pharmacy.
Treble Damages and Private Standing: The bill introduces a private right of action, allowing individuals alleging damages from vertical integration to sue for treble damages and attorney fees.

State-Level Bans and the ERISA Preemption Legal Battleground

At the state level, Tennessee enacted the Freedom, Access, and Integrity in Registered Pharmacy (FAIR Rx) Act (S.B. 2040) on May 22, 2026. Mirroring the federal bill, the FAIR Rx Act prohibits any entity from owning or controlling both a pharmacy and a PBM or health insurer (applying to ownership interests over 5%), with an effective date of July 1, 2028. Tennessee follows Arkansas as the second state to pass a structural ban on vertical integration.

In response, major PBMs are weaponizing federal preemption to block these state-level restrictions. On May 8, 2026, UnitedHealth Group's Optum Rx and its group purchasing organization (GPO) affiliate, Emisar Pharma Services, filed a federal lawsuit to block enforcement of California’s comprehensive PBM reform law, S.B. 41. Optum Rx argues that key provisions of S.B. 41—including restrictions on formulary exclusivity, anti-steering mandates, and prohibitions on spread pricing—are preempted by the federal Employee Retirement Income Security Act (ERISA).¹² This lawsuit relies heavily on the Sixth Circuit's April 15, 2026, ruling in McKee Foods Corp. v. BFP Inc., which held that ERISA preempts Tennessee’s anti-steering pharmacy laws.

Optum Rx's Defensive Pivot to Transparent Pricing

As a defensive measure against this regulatory onslaught, Optum Rx announced a voluntary "transparent pharmacy care model" on May 11, 2026. This model offers clients per-member-per-month (PMPM) flat fees independent of drug prices or prescription volume, alongside full transparency into manufacturer rebates and fees earned by Optum Rx and its GPO.³ This represents a proactive attempt to de-risk the business by transitioning away from controversial spread pricing and rebate-retention models before they are legally outlawed.

An instance of State-level pharmacy regulations crumble against the federal preemption shield of ERISA. — Major healthcare service providers actively sue to block state-level reforms by arguing they interfere with uniform benefit administration under ERISA. ↩︎
An instance of State healthcare regulations cannot bypass federal preemption without masquerading as professional practice licensure. — The litigation highlights how state laws regulating vertical healthcare structures are consistently challenged and blocked based on federal preemption. ↩︎
An instance of Opaque rebate retention collapses the moment regulators force transparent net-cost pricing. — Optum Rx transitioned to a flat-fee model to proactively guard against incoming federal and state-level bans on spread pricing and rebate retention. ↩︎

Part of

This finding is an example of a pattern recurring across your work:

Medical loss ratio limits collapse when premium revenues flow to internal clinical platforms.

It showcases the legislative response aiming to crack down on the common ownership and internal profit-routing of vertically integrated health companies.

Revision history